• Insurance technology market is rapidly growing, creating innovation and opportunity in the digital insurance sector
• InsuraGuest’s working to expand its product offering and the reach of its platform via brokers and agents
• In the hospitality sector, company’s insurance products cover a wide range of issues, from theft and damage of personal property to accidental medical expenses and accidental death and dismemberment

The insurtech market is growing rapidly, and specialized insurance provider InsuraGuest Technologies Inc. (TSX.V: ISGI) is riding the wave of technological innovation in the digital insurance sector. The company’s insurance systems target specific niches and is now moving to expand offerings to a wider audience and additional revenue streams. The company aims to move into providing software technology applicable to multiple insuring specialist sectors, of which their current support of the hospitality insurance sector is an example.

The different digital insurance needs of various markets allow InsuraGuest Technologies and other insurtech companies to provide added value by tailoring to specific needs of clients while building systems that can be adapted elsewhere.

Approximately $16.5 billion has been invested in the sector over the past 10 years. What is more, the pace of investment is on the rise (http://ibn.fm/fsRXv), with $2.2 billion raised in the first half of 2019 alone (http://ibn.fm/YWYxa). This increase is driven by outside and inside pressure for change and more innovation in the insurance market.

The growing rate of investment is essential, given that an estimated 90% of the resources insurance companies invest in technology are going into maintaining existing approaches instead of exploring real innovation. InsuraGuest, however, is adding value by offering the opposite approach – integrating insurance innovation and SaaS in a single flexible package.

InsuraGuest Technologies’ platform is set up to deliver digital insurance packages directly to partners on a business-to-business basis, and it has the technology to expand its platform to the business-to-consumer markets in the future. The company also allows agents and brokers to sign up instantly online through its fully automatized agency/broker software program. These brokers and agents then become channels to take InsuraGuest’s insurance out to their own customers, speeding up the process of distributing the insurtech innovator’s platform and products.

The company’s insurtech platform is already fully operational in the hospitality sector, where InsuraGuest offers hotels and vacation rentals easy access to the insurance coverage policies they need to protect their properties, making it easier to arrange and deliver new insurance products. Technology takes away much of the burden of arranging insurance and members can buy into all the support systems they need instead of buying a single standalone product and then struggling with making it work.

Traditional travelers’ insurance doesn’t cover a number of things that can happen inside hotels or other travel properties, putting both the traveler and the hotel or property owner at risk. People often mistakenly assume that accidents happening at such a property are covered by the property owner’s general liability or homeowner policy. InsuraGuest’s proprietary platform delivers specialized Hospitality Liability coverages that protect the hotel or vacation rental property which guests benefit from the property being protected during their stay. The Hospitality Liability Policy covers a wide range of issues, from theft and damage of personal property to accidental medical expenses, death and dismemberment.

About 59% of property managers in Europe use a specialist property management system (PMS), into which insurance typically isn’t integrated. It therefore needs to be managed separately. Recognizing this opportunity, InsuraGuest Technologies found a solution by integrating its digital insurance with 71 different PMSs around the world, gaving the software access to potentially deliver their insurance coverages to millions of rooms. This way, the process of obtaining insurance melds seamlessly with other relevant processes (http://ibn.fm/Ptvon), while allowing for significant growth opportunities for the company in larger hospitality markets.

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Dedicated to the health-conscious consumer
• Expanded preclinical trial pipeline by entering into definitive agreement to acquire Tassili Life Sciences Corp
• Expanding brand into alternative medicine by entering into a definitive agreement to acquire Novoformulations

Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a Canada-based company dedicated to the distribution of artisanal medicinal mushroom-infused products, is expanding its portfolio with the health-conscious consumer in mind. SHRM recently entered into a definitive agreement to acquire two separate companies: Tassili Life Sciences Corp. and Novoformulations, a specialty biotechnology company.

SHRM recently announced it has expanded its preclinical trial pipeline by entering into a definitive agreement to acquire Tassili Life Sciences Corp. (http://ibn.fm/ryRia). Under the terms of the agreement, SHRM will acquire all of the issued and outstanding shares of Tassili, equaling 16 million common shares. Tassili has filed four provisional psilocybin patents, including one relating to its work with the University of Miami around the treatment of mild traumatic brain injury (mTBI) and post traumatic stress disorder (PTSD).

Tassili is already in a partnership with a multidisciplinary team of scientists and physicians at the University of Miami that is working on developing effective treatments of mTBI with PTSD and standalone PTSD. Under a collaborative research agreement that will eventually include human clinical trials, the university will study the combination of psilocybin and cannabidiol in treating these conditions. Tassil will retain exclusive rights to inventions, data and IP discovery resulting from the studies.

“Mild traumatic brain injury, especially concussion, is a significant cause of morbidity worldwide,” Dr. Michael Hoffer, the professor leading the study at the University of Miami, stated in a release. “What many do not realize is that TBI often occurs alongside PTSD. Up to 40% of people impacted by mTBI, a head injury causing a temporary change in mental status or consciousness, or TBI in general, also suffer from PTSD. This combination of mTBI and PTSD is even more common in U.S. military members and presents a vast patient population to service and potentially heal with our novel therapeutics under development.”

The goal is to shift the perception of psychedelics through the establishment of scientific underpinnings of psilocybin and cannabidiol’s medical benefits. The next step is to develop a prescription-based therapeutic medicine for mTBI with PTSD as well as a number of other disorders.

In addition to acquiring Tassili, SHRM has entered into a definitive agreement to acquire Novo Formulations Ltd. (http://ibn.fm/lVrGA). Novoformulations is a specialty biotechnology company focused on developing novel and innovative delivery systems for the pharmaceutical and nutraceutical industries. This acquisition will accelerate the architecture of SHRM’s patent portfolio. Under the terms of the agreement, SHRM will acquire all of the issued and outstanding shares of Novoformulations, for a total of 12.5 million common shares in the capital of the company.

Novoformulations, made up of PhD and technician-level scientists, is currently working with ketamine, anesthetics, adaptogenics, and other pharmaceutical and natural molecules. The company is actively formulating, developing and commercializing bioavailable delivery platforms.

“The existing infrastructure inherited from these recent acquisitions positions us as a leading participant throughout the entire alternative medicine life cycle,” SHRM CEO Gareth Birdsall stated in a news release. “The end result will be a turnkey solution that incorporates both standardized ingredient mixtures and pharmaceutical-grade products that can now be marketed via a variety of proprietary delivery systems. The addition of Novoformulations allows Champignon to deliver medications in a safer, more effective and more expeditious manner than our peers, from bench top in the laboratory, to preclinical and clinical trials. We are intent on the commercialization of products throughout North America, as rapidly as is safely and effectively practicable.”

Champignon seeks opportunities to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health-care and pharmaceutical products. The company’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom industry with a selection of mushroom-infused teas and accessories; SHRM is also expanding its preclinical trial pipeline and branching out into alternative medicine and pharmaceuticals.

For more information, visit the company’s website at www.ChampignonBrands.com

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

• SHRG produces exclusive hormone-based nutritional products designed to improve physical, mental health
• Patented line of D.O.S.E. products formulated with key hormones: dopamine, oxytocin, serotonin and endorphins
• Company posts sales revenues of $169 million since December 2017 launch

Sharing Services Global Corporation (OTCQB: SHRG), a diversified direct-sales holdings company, is transforming typical sales strategies and adapting to challenging times by focusing on elevating happiness for its customers through mood-elevating nootropics products. Through its subsidiary Elepreneurs LLC, SHRG trains and supports its independent sales representatives, called Elepreneurs, to help fulfill its mission to elevate the lives of their customers through proprietary nutritional products formulated to improve physical and mental health.

Elevacity Global LLC, a second SHRG subsidiary, offers a patented line of D.O.S.E. products formulated with four hormones implicit in the brand name: dopamine, oxytocin, serotonin and endorphins. Developed by a team of experienced nutritionists, doctors, chemists, naturopaths, pharmacists and food scientists, products such as its Elevate Smart Coffee contain a proprietary blend of nootropic ingredients designed to assist with mental clarity, memory and energy.

“Within a few sips, many people say they just feel better, happy, energized and focused,” Elepreneurs Chief Experience Officer Sylvia McGrath stated in a news release (http://ibn.fm/9AfqG). “When new customers start feeling this good about an affordable product, oftentimes they feel compelled to tell other people about it. It’s an instant-impact product that oftentimes turns into an instant-impact business.”

SHRG is increasingly focused on its mission in light of current global events that have left many people isolated and depressed (http://ibn.fm/1PuCG). The company’s business model, which offers home-based entrepreneurship, online video meetings and employment flexibility, continues to serve the goals of the company despite changing economic conditions, and its mission of elevating the well-being of its employees and customers is more important – and timely – than ever.

“Are there hard days? Yes, but the good days far exceed the hard days,” Elepreneurs president Keith Halls recently observed. “It’s about more than just sharing a cup of happy coffee. It’s about helping others lead happier lives.”

Since the company’s launch in December 2017, Elevacity products have totaled $169 million in sales revenues through the Elepreneurs and Elevacity subsidiaries. Strong sales continued into 2020 with the company posting fiscal third-quarter revenues of $31.6 million for the three months ended January 31, 2020, an increase of 22% when compared to the comparable quarter of fiscal 2019 (http://ibn.fm/q1kLh).

With plans to expand into foreign markets, the company is confident in fulfilling its mission to positively affect as many lives as possible through its compelling Elepreneur opportunity and powerful Elevacity brand of health and wellness products.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Company boasts significant first-mover advantage in proprietary web-based e-commerce platform segment
• Revenue growth driven by increases in the number of registered users and acquisition of Pharmacy
• Currently adding 100+ pharmacies per month to its online purchasing platform
• Trxade seeking FDA approval for antibody rapid test that can be used for COVID-19 patients

Trxade Group Inc. (NASDAQ: MEDS) is an integrated drug delivery, procurement, and health care platform that offers health care buyers and sellers of pharmaceuticals increased profit margins. The company has developed a proprietary web-based e-commerce platform (S2P – Supplier to Pharmacy) designed to help pharmacies reduce expenses by identifying the best available supplier prices for prescription drugs nationwide.

Leveraging this approach and a robust technology based on predictive data analytics, optimum buyer/seller pricing algorithms and product availability information, Trxade is uniquely positioned to become a leading e-commerce service provider in the $500 billion U.S. pharmaceutical industry overview 2019 (http://ibn.fm/qIqYt), which comprises more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. The company targets independent pharmacies on the market, which collectively spend more than $78 billion a year (http://ibn.fm/98LSL) on branded and generic medication.

With more than 12,100 independent pharmacies registered so far, Trxade’s platform allows its members to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving them money by taking advantage of best purchase pricing.

Revenue growth on the S2P platform comes from two primary sources: increases in the number of registered users and growth in the utilization rate of the trading platform among registered users according to company data. Adding approximately 100 new pharmacies per month, Trxade’s aim is to ultimately reach most, if not all, of the 24,000 independent pharmacies on the market.

The approach is part of Trxade’s efforts to be one of the driving forces behind a nationwide reduction of pharmaceutical and health care costs. Especially in the current economic climate where the health care system is under strain as a result of the ongoing pandemic, keeping medication costs is essential. To this end, the company is committed to developing its portfolio of products and services to drive value and growth for all members, employees and investors.

Trxade’s wholly owned subsidiary, Integra Pharma Solutions, has filed for an Emergency Use Authorization with the U.S. Food and Drug Administration in collaboration with its partnered manufacturer of the SARS-CoV-2 IgM/IgG Antibody Rapid Test Kit (http://ibn.fm/6OuL3). Currently, the test is intended to aid in presenting a qualitative overview of antibody presence in patients who have possibly been infected by the coronavirus (COVID-19). In addition, the company aims to provide relief via another subsidiary, Bonum Health, a virtual telemedicine provider that can help patients access certified physicians and receive medical advice and prescriptions without needing to leave their homes.

This follows another innovative initiative launched via Bonum Health – the Bonum Health Hub developed in partnership with Tampa Bay-based independent retail pharmacy chain Benzer Pharmacy. Under the agreement, Bonum and Benzer set up Health Hubs in urban and rural areas to offer care to patients who can afford neither primary nor collaborative care.

As the U.S. health care market, currently valued around $4 trillion (http://ibn.fm/YqY21) is expected to continue growing in the context of an aging population, related expenses and drug costs are expected to increase at a considerable rate. This will provide significant opportunity for the Trxade model of price visibility and profit optimization, which could be successfully adopted on a wide scale by medical products and services providers.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

The next time you are looking to acquire a new vehicle, how will you go about it after this pandemic subsides? Would you head to the nearest dealership to compare their models on offer or would you rather shop online?

Americans have already answered that question. Due to the COVID-19 pandemic, new car sales in the United States declined by 29% as of mid-March, relative to the same period last year (http://ibn.fm/QeKuM). Sales are dropping sharply as the COVID-19 pandemic forces dealership closures and shelter-at-home orders confines potential buyers to their homes. And that is putting a new consumer trend into stark relief: a recent survey carried out by Cars.com showed that 48% of potential car buyers are now willing to consider negotiating for, and purchasing, a vehicle online (http://ibn.fm/Gxu6j) with the figure rising to 62% when only millennials are taken into account.

PowerBand Solutions Inc. (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA), a fintech pioneer, is on the cutting edge of this trend. It is revolutionizing how vehicles are sold online and helping disrupt the automotive industry’s antiquated business model by offering customers a simple way to buy, sell, trade and lease their car on their smart phone or from home. PowerBand makes acquiring a vehicle as easy as purchasing a product on Amazon (http://ibn.fm/4rRig).

“It is clear that the automotive industry needs to embrace a better way to buy, sell, trade and lease cars,” PowerBand CEO Kelly Jennings stated in a news release. “People want to be able to shop for cars online, using their smartphones or laptops. PowerBand can help consumers do that, meeting their obvious desire for a fast, cloud-based platform to buy, lease, sell or trade their cars and trucks.”

Powerband also allows instant, online and highly customized virtual auctions which simultaneously markets a vehicle to a vast network of the industry’s top used car buyers. These 20-minute virtual auctions eliminate the need for dealerships to hold physical auctions, reducing the high costs and lengthy timeframe associated with that more traditional sales format. Moreover, the ability to auction used vehicles in a quick and efficient manner has allowed dealerships to save on the expense of auctions – in turn lowering the cost for potential customers looking to lease or buy a new car.

Powerband is also making it as easy to lease a car on-line as buying a product on Amazon, primarily thanks to its July 2019 acquisition of a majority stake in MUSA Holdings LLC, an advanced technology platform that has transformed the new and used vehicle leasing industry in the United States. MUSA will allow a customer to choose a vehicle and then proceeds to calculate a lease, auto-decisions the application, provides an approval back to the dealership, and prefills a lease contract accurately. As a result, PowerBand and MUSA’s revolutionary online marketplace allows customers to bypass unnecessary middlemen, receive transparent pricing information and complete the lease approval in as little as eight seconds. This industry-leading performance compelled Tesla (NASDAQ: TSLA) two years ago to designate MUSA as its only independent leasing partner in the U.S.

Simply put, PowerBand finds itself on the cutting edge of a new trend in the automotive retail sector. As customers increasingly choose to stay away from crowded car dealerships and migrate to online sales channels, especially in light of coronavirus concerns, PowerBand offers the go-to platform for car and truck sales, leases and auctions. The company has the unique ability to use MUSA’s lease origination platform to allow online customers to choose and lease vehicles within seconds, sell pre-owned vehicles through D2D Auto Auctions, LLC’s proprietary online auction platform, a 50/50 joint venture between PowerBand and Bryan Hunt, Director of J.B Hunt Transport, and help dealerships sell their off-lease vehicle inventory to their widespread network in a rapid and efficient manner. With the car dealership industry’s online transformation rapidly afoot, PowerBand is well-placed to lead the way.

For more information, visit the company’s website at www.PowerBandSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to PWWBF are available in the company’s newsroom at http://ibn.fm/PWWBF

• POAI’s Helomics division progresses toward critical milestone in CancerQuest2020 initiative
• Predictive models immensely valuable to pharmaceutical industry, improving drug evaluation without incurring high laboratory costs
• POAI is bringing precision medicine to the treatment of cancer for patients of today and tomorrow

Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced continued progress by its Helomics subsidiary toward the goal of developing an AI-driven predictive model of ovarian cancer. This achievement will be a key milestone for the company’s CancerQuest2020 initiative (http://ibn.fm/mENY6).

CancerQuest2020 is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome leveraging Helomics’ huge knowledge base of tumor profiles. Predictive models embody the knowledge from these profiles to create a “computational expert” or a “virtual patient” that can be queried. Predictive models such as these are of high value to pharmaceutical companies as they can be used to quickly select patients for clinical trials and assess potential new drugs or biomarkers computationally (“in silico”) before initiating expensive laboratory experiments. In short, Helomics’ predictive models will save time and money in the search for new targeted therapies.

Using the power of AI, the model draws on data generated from over 150,000 tumor cases obtained from over 15 years of clinical testing on living patient tumors, bringing together valuable multi-omic data, i.e. drug response, genomic (mutations), transcriptomic (gene expression) and tissue-omic (tumor pathology) profiles to predict drug response and outcome.

“Despite some headwinds imposed by the current COVID-19 pandemic, the Helomics team has been working diligently to meet both our clinical testing priorities for ovarian cancer patients and their oncologists, as well as maintaining progress on data generation for CCQ2020,” Helomics President Gerald Vardzel stated in a news release (http://ibn.fm/957XJ). “Also, we received our formal letter of compliance today for our CLIA (Clinical Laboratory Improvement Amendments) recertification survey conducted on March 10, 2020. Results of this survey showed all requirements were met and that we were in full compliance with applicable regulations,” added Helomics medical director and vice president of operations and pathology services Dr. Arlette Uihlein.

“In a true team effort across the company we have made solid progress on our CCQ2020 milestones this quarter; we ramped up our sequencing effort as part of our UPMC-Magee collaboration; initiated further digitization of our histopathology slide collection; renewed our collaboration with Genomics England 100,000 genomes project and completed development of our AI model build framework so we can train millions of potential models at scale using cloud resources,” indicated Helomics CTO Dr. Mark Collins.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Sigma Labs awarded two new patents on the same day for PrintRite3D(R) software
• PrintRite3D(R) further protected and positioned as the leading solution for quality control impediments to 3D metal printing industry
• Sigma Lab’s IP portfolio now expanded to 11 issued and 24 pending patents
• 3D manufacturing playing critical role in shortening, simplifying complex global supply chains as result of COVID-19

Sigma Labs Inc. (NASDAQ: SGLB), a software company that specializes in the development of real-time computer-aided inspection software for 3D metal printing, has further solidified its first-mover status in the industry through the acquisition of two new patents for its flagship software, PrintRite3D(R).

Positioned as the definitive quality control software solution for 3D metal printing, PrintRite3D(R) detects defects and anomalies during the manufacturing process in real-time, giving operators an accurate, comprehensive and reliable quality assurance solution. PrintRite3D(R) can save time, money and valuable raw materials – in addition to acting as a catalyst to accelerate the industry’s transition past the prototype phase and into serial production.

Quality control remains one of the primary impediments holding back the 3D metal printing industry due to the high cost of rejected parts and time spent in the post-production inspection phase. Since the 3D printing process creates objects by applying layers of raw material on top of each other, the potential for errors is high without in-process quality control measures in place that detect anomalies in real time that allow for error correction.

PrintRite3D(R) is the leading solution that addresses this issue through in-process monitoring, analysis and feedback, giving operators the critical information required to observe the production process and receive alerts as PrintRite3D(R) detects errors or anomalies taking place in real time. This allows additive manufacturers to identify and fix – or stop – quality inconsistencies in the manufacturing process so that production quality can be optimized and modified, lowering rejected output and saving money – necessary steps for the industry to scale up and realize its profit potential.

In addition to transforming the manufacturing process, 3D printing is also emerging as a solution to supply chain issues resulting from events surrounding COVID-19 (http://ibn.fm/PDQFu). Sigma Labs executive chairman Mark K. Ruport recently commented (http://ibn.fm/vR0B8) that “3D manufacturing will become more and more critical to the major economies of the world in order to shorten and simplify complex supply chains by manufacturing metal parts closer to home.”

“The recent crisis highlights the fact that economies that are too interdependent are subject to significant slowdowns in times of crisis,” Ruport noted. “The fact that our technology could play a role in accelerating the industrialization of 3D metal printing validates the investments that we have made in developing and commercializing our PrintRite3D(R) product.”

The new patent additions significantly boost Sigma Labs’ already robust intellectual property portfolio consisting of 11 presently issued and 24 pending patents, significantly protecting the technology commonly viewed to be essential for industry growth. Accordingly, PrintRite3D(R) is being evaluated by many tier-1 OEM enterprises in the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries. Besides its expanding client list, Sigma Labs continuously seeks to enlarge its footprint in the market through strategic partnerships with additive manufacturing hardware and software vendors, research institutions and universities.

In less than two decades, 3D printers have evolved from costing several hundred thousand dollars and using only plastic (http://ibn.fm/rKbsq) to providing hundreds of parts for some of the most fuel-efficient jet engines on the planet (http://ibn.fm/MLtzD). As the leading provider of quality control solutions for 3D metal printing, Sigma Labs continues to strengthen its position on the frontlines of the industry as it rapidly transforms the $12 trillion manufacturing landscape (http://ibn.fm/iPoWk).

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• Largest producer of uranium in the United States (2017-2019); assets accounted for over one-third of nation’s supply since 2006
• Leading U.S. vanadium producer in 2019 with flexibility to respond to evolving markets
• Diverse business opportunities, including alternate feed materials recycling, land cleanup and rare earths, which all have significant potential to drive significant cash flow
• Positioned to benefit from Trump Administration’s pursuit of $1.5B over 10 years to purchase uranium from U.S. miners, along with other U.S. government support of domestic production
• Strong cash, working capital and inventory positions
• Proven track-record of sustained U.S. market leadership

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

• White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
• Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
• Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

• Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
• Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
• Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

• La Sal Complex (Utah)
• Whirlwind Mine (Colorado/Utah)
• Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

1. Paul Goranson, COO
   W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

For more information, visit the company’s website at www.EnergyFuels.com

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Trxade Group Inc. is an expanding healthcare tech platform builder that aims to assist small, community-based pharmaceutical businesses and the patients who comprise their customers through drug pricing and delivery operations as well as telemedicine consultations
• Trxade Group recently announced its year-end financial statement for 2019, noting revenues had grown nearly double over the previous year, from $3.83 million to $7.43 million
• The company is celebrating a decade in operation with four platforms that are integrated synergistically to serve the needs of rural and neighborhood-centric health businesses on a subscription basis
• Trxade’s telehealth services enable patients to access licensed medical professionals from virtually anywhere via personal technology for minor health needs, ensuring them that during a time of pandemic they won’t need to risk unnecessary exposure to the COVID-19 virus at facilities treating other patients
• Trxade recently announced its uplisting to the Nasdaq Capital Market and rang the exchange’s opening bell as part of its efforts to continue building its financial resources

Before the pandemic sweep of the novel coronavirus (or COVID-19) began causing alarm among health policy advisers and care providers, leading to restrictions on movement for the general population, forward-thinking health services provider Trxade Group Inc. (NASDAQ: MEDS) was building a synergistic set of operational platforms to help expand the reach of care providers to underserved communities via online “telemedicine” technology and medicinal delivery services that now seem prescient in their nature.

Amid Trxade Group’s efforts to expand its platforms, the company saw continued revenue growth that culminated in its recent uplisting to the Nasdaq Capital Market and an announcement that it expected gross proceeds of $5.2 million from a public offering’s sale of common stock (http://ibn.fm/N1kFG).

On March 30, Trxade announced its year-end financials, reporting that annual revenues from continuing operations grew from $3.83 million in 2018 to practically double that amount in 2019 at $7.43 million. The company also saw operating income rise from a loss of ($87,616) in 2018 to a gain of $125,244 (http://ibn.fm/1N4TM).

The improved financial picture reflects Trxade’s efforts to make healthcare services affordable and accessible across all 50 states coincidental to price transparency mechanisms and increased profit margins for buyers and sellers of pharmaceuticals.

As the company completes its first decade of operations, it has grown to enfold four platforms that are integrated to best serve the needs of rural and neighborhood-centric health businesses. The platforms are the company’s trademarked trading platform that serves 12,100 registered pharmacies, a licensed virtual (online) wholesaler, web-based telehealth services through the company’s Bonum Health subsidiary and the company’s DelivMeds same-day/mail order pharmaceuticals delivery service.

“In addition to increased revenue growth from our companies, Trxade Group achieved a number of significant milestones around innovation and enhancements in 2019 that add even more value to our role as a strategic provider to independent pharmacies and lower cost healthcare to all consumers,” Board Chairman and CEO Suren Ajjarapu stated in a news release. “We believe our platform will become even more important for our customers in the years to come. We have a clear vision of our strategy and the opportunities ahead and look forward to another successful year of growth.”

The company’s report states it added 3,266 new independent pharmacies to its trading platform in 2019 and saw a 23.07 percent rise in pharmacy purchasers during the year, as well as an 8.86 percent increase in purchases per pharmacy on the trading platform.

On March 10, Trxade announced (http://ibn.fm/kH95J) that it was launching a new service through Bonum and DelivMeds to provide subscribers with three premium medical teleconferencing visits and free prescription delivery through company subsidiaries each month under the standard membership rate, freeing patients from unnecessary exposure to viral illnesses such as COVID-19 or the seasonal flu and RSV at hospitals and urgent care facilities when consulting for “clinical needs and minor visits that do not require conventional appointments.”

The telehealth services can provide patients with private access to board-certified physicians from virtually anywhere, using the patients’ personal communication technology.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• Sigma announcement outlines operational, financial highlights
• Management calls 2019 “milestone year” and believes that SGLB technology is on forefront of next industrial revolution
• Company anticipates seeing continued momentum from both end users and additive manufacturing machine OEMs

Sigma Labs (NASDAQ: SGLB), a leading developer of quality-assurance software for the commercial 3D-printing industry, announced its financial and operational results for Q4 and fiscal year ending December 31, 2019 (http://ibn.fm/A6ck8).

The announcement outlined several key highlights for the company, including entering into a joint sales agreement with Materialise, being awarded Phase 2 test and evaluation program status from different manufacturers and being selected by a major international OEM machine manufacturer to integrate Sigma’s exclusive PrintRite3D(R) quality-assurance software program as part of an evaluation process for a broader rollout.

“2019 was a milestone year for Sigma Labs, as we transitioned from an R&D-focused company into a full-fledged commercial enterprise, complete with a validated, user-friendly product with customers who are some of the largest industrial companies in the world and in the top echelon of additive manufacturing OEMs,” SGLB executive chairman Mark Ruport stated in a news release. “I am particularly proud of our recently announced joint sales agreement with Materialise, a leading provider of additive manufacturing software and 3D-printing solutions, to commercialize our newly integrated PrintRite3D quality-assurance technology within the Materialise control platform. I continue to see intense interest from industry players of every size, proving the absolute value inherent to our technology.”

The announcement mentioned additional highlights for the quarter, which included being selected by a major Japanese OEM machine tool manufacturer for a test and evaluation program of PrintRite3D Real Time Melt Pool Analytics and being awarded several key contracts, including a contract to implement PrintRite3D in collaboration with university research centers at the Northwestern University, a contract with the Mississippi State University Center for Advanced Vehicular Systems, and a contract with the VTT Technical Centre of Finland to install PrintRite3D at the VTT 3DMetalprint Centre for Additive Manufacturing.

Year-end highlights included being chosen by Airbus to deploy the PrintRite3D version 5.0 product into a laser powder bed printer as part of a testing and evaluation program, launching the breakthrough version 5.0 quality-assurance software at the RAPID+TCT 3D Printing and Additive Manufacturing Conference and realizing third-party validation of its PrintRite3D software through a Defense Advanced Research Project Agency research study conducted in collaboration with Honeywell Aerospace.

“Sigma is truly on the forefront of the next industrial revolution, addressing a major cost headwind to allow additive manufacturing technology to further scale and revolutionize many industries,” added Ruport, who noted that, given the COVID-19 crisis, Sigma’s principal commitments are to its employees, shareholders and customers. “We continue to see momentum from both end users, who constantly serve as a reminder of the value of our technology, and from additive manufacturing machine OEMs, who see inherent value in integrating PrintRite3D into their machines. Revenues from either of these avenues could build rapidly, but more importantly could provide for a repeatable revenue stream with exceptional gross margins.”

Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided-inspection (CAI) solutions known as PrintRite3D for 3D-advanced manufacturing technologies. SGLB’s advanced, computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB